Literature DB >> 18059341

Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor.

C W Menges1, D J McCance.   

Abstract

The Raf-mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)-AKT pathways are two downstream effectors of the small GTPase Ras. Although both pathways are positively regulated by Ras, the Raf-MAPK and PI3K-AKT pathways have been shown to control opposing functions within the cell, suggesting a need for cross-talk regulation. The PI3K-AKT pathway can inhibit the Raf-MAPK pathway directly during processes such as muscle differentiation. Here we describe the ability of the Raf-MAPK pathway to negatively regulate the PI3K-AKT pathway during cellular arrest. Constitutive activation of Raf or methyl ethyl ketone 1 (MEK1) leads to inhibition of AKT and cellular arrest. Furthermore, we show that activation of Raf-MEK1 signaling causes negative feedback inhibition of Ras through the ephrin receptor EphA2. EphA2-mediated negative feedback inhibition is required for Raf-induced AKT inhibition and cell cycle arrest, therefore establishing the inhibition of the Ras-PI3K-AKT pathway as a necessary event for the Raf-MEK1-regulated cellular arrest.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059341     DOI: 10.1038/sj.onc.1210957

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

Review 3.  Regulation and misregulation of Eph/ephrin expression.

Authors:  Dina N Arvanitis; Alice Davy
Journal:  Cell Adh Migr       Date:  2012-03-01       Impact factor: 3.405

Review 4.  Eph receptor signaling and ephrins.

Authors:  Erika M Lisabeth; Giulia Falivelli; Elena B Pasquale
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

5.  Structure-activity relationship analysis of peptides targeting the EphA2 receptor.

Authors:  Sayantan Mitra; Srinivas Duggineni; Mitchell Koolpe; Xuejun Zhu; Ziwei Huang; Elena B Pasquale
Journal:  Biochemistry       Date:  2010-08-10       Impact factor: 3.162

Review 6.  Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics.

Authors:  Erika Gucciardo; Nami Sugiyama; Kaisa Lehti
Journal:  Cell Mol Life Sci       Date:  2014-05-04       Impact factor: 9.261

7.  Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer.

Authors:  Helenia Ansuini; Annalisa Meola; Zeynep Gunes; Valentina Paradisi; Monica Pezzanera; Stefano Acali; Claudia Santini; Alessandra Luzzago; Federica Mori; Domenico Lazzaro; Gennaro Ciliberto; Alfredo Nicosia; Nicola La Monica; Alessandra Vitelli
Journal:  J Oncol       Date:  2010-01-14       Impact factor: 4.375

8.  Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

Authors:  Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Jeffrey Eastham-Anderson; James E Cupp; Yuxin Liang; David P Davis; Klaus P Hoeflich; Somasekar Seshagiri
Journal:  PLoS One       Date:  2009-05-27       Impact factor: 3.240

9.  Generation of dopamine neurons with improved cell survival and phenotype maintenance using a degradation-resistant nurr1 mutant.

Authors:  A-Young Jo; Mi-Young Kim; Hyun-Seob Lee; Yong-Hee Rhee; Jeong-Eun Lee; Kwang-Hyun Baek; Chang-Hwan Park; Hyun-Chul Koh; Incheol Shin; Yong-Sung Lee; Sang-Hun Lee
Journal:  Stem Cells       Date:  2009-09       Impact factor: 6.277

10.  Dissecting the signaling events that impact classical nuclear import and target nuclear transport factors.

Authors:  Mohamed Kodiha; Dan Tran; Andreea Morogan; Cynthia Qian; Ursula Stochaj
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.